These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

930 related items for PubMed ID: 33781830

  • 1. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
    Song Z, Jia G, Ma P, Cang S.
    Life Sci; 2021 Jul 01; 276():119399. PubMed ID: 33781830
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2019 Dec 09; 12(1):135. PubMed ID: 31818312
    [Abstract] [Full Text] [Related]

  • 5. Exosome-transmitted circVMP1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting miR-524-5p-METTL3/SOX2 axis.
    Xie H, Yao J, Wang Y, Ni B.
    Drug Deliv; 2022 Dec 09; 29(1):1257-1271. PubMed ID: 35467477
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L, Xu Z, Wu G, Chen X, Huang Y, Wang Y, Jiang W, Ke B.
    BMC Cancer; 2017 Feb 15; 17(1):138. PubMed ID: 28202053
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tumor-derived exosomal miR-619-5p promotes tumor angiogenesis and metastasis through the inhibition of RCAN1.4.
    Kim DH, Park S, Kim H, Choi YJ, Kim SY, Sung KJ, Sung YH, Choi CM, Yun M, Yi YS, Lee CW, Kim SY, Lee JC, Rho JK.
    Cancer Lett; 2020 Apr 10; 475():2-13. PubMed ID: 32004570
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. CAFs-Derived Exosomal miRNA-130a Confers Cisplatin Resistance of NSCLC Cells Through PUM2-Dependent Packaging.
    Zhang T, Zhang P, Li HX.
    Int J Nanomedicine; 2021 Apr 10; 16():561-577. PubMed ID: 33542625
    [Abstract] [Full Text] [Related]

  • 13. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X, Chen Y, Shen Y, Tantai J.
    Cell Death Dis; 2019 Jun 03; 10(6):429. PubMed ID: 31160576
    [Abstract] [Full Text] [Related]

  • 14. Downregulation of exosomal miR‑1273a increases cisplatin resistance of non‑small cell lung cancer by upregulating the expression of syndecan binding protein.
    Zhao X, Li M, Dai X, Yang Y, Peng Y, Xu C, Dai N, Wang D.
    Oncol Rep; 2020 Nov 03; 44(5):2165-2173. PubMed ID: 32901857
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH, He SY.
    Eur Rev Med Pharmacol Sci; 2020 Mar 03; 24(6):3130-3142. PubMed ID: 32271431
    [Abstract] [Full Text] [Related]

  • 17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W, Ping W, Tian Y, Zou W, Liu J, Zu Y.
    Cell Physiol Biochem; 2018 Mar 03; 51(5):2160-2171. PubMed ID: 30522099
    [Abstract] [Full Text] [Related]

  • 18. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
    Yu L, Chen D, Song J.
    Thorac Cancer; 2020 Mar 03; 11(3):603-611. PubMed ID: 31953899
    [Abstract] [Full Text] [Related]

  • 19. MiR-146a-5p level in serum exosomes predicts therapeutic effect of cisplatin in non-small cell lung cancer.
    Yuwen DL, Sheng BB, Liu J, Wenyu W, Shu YQ.
    Eur Rev Med Pharmacol Sci; 2017 Jun 03; 21(11):2650-2658. PubMed ID: 28678319
    [Abstract] [Full Text] [Related]

  • 20. microRNA-381 suppresses the growth and increases cisplatin sensitivity in non-small cell lung cancer cells through inhibition of nuclear factor-κB signaling.
    Huang RS, Zheng YL, Zhao J, Chun X.
    Biomed Pharmacother; 2018 Feb 03; 98():538-544. PubMed ID: 29287202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.